. , . , . , , , . . , .
, , . .
.
, (, α- β-, , ) , . , , , .
- . . , , , , , α- β-, .
.
, . . , , , . . , , , . , , . , , . - . 5-10 / . , , , , . , , . 5, 10 / , 4-6 5 /. 10 , . . CYP450 2D6 34. 2 , . . , , , ( - ()) .
|
|
, .
. [78]
. , .
. , , 2 . . . 2 3,5 .
- , . 160 /, . . .
, 10 4 . . 40 4 . , ( ).
50% , , , 6 . 25% ( ). , , 100-200 /, , . , , , .
, P450. .
|
|
.
.
Chiarello RJ, Cole JO. The use of psychostimulants in general psychiatry. Arch Gen Psychiatry 1987; 44:286.
Forrest WH Jr, Brown BW Jr, Brown CR, et al. Dextroamphetamine with morphine for the treatment of postoperative pain. N Engl J Med 1977; 296:712.
Katon W, Raskind M. Treatment of depression in the medically ill elderly with methylphenidate. Am J Psychiatry 1980; 137:963.
Kaufmann MW, Marray GB, Cassem NH. Use of psychostimulants in medically ill depressed patients. Psychosomatics 1982; 23:817.
Mannuzza S, Klein EG, Bessler A, et al. Adult outcome of hyperactive boys: educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 1993; 50:885.
Mattes JA, Boswell L, Oliver H. Methylphenidate effects on symptoms of attention deficit disorder in adults. Arch Gen Psychiatry 1984; 41:1059.
Spencer T, Wilens , Biederman J, et al. A double-blind, cross-over comparison of methylphenidate and placebo in adults with childhood onset attention deficit hyperactivity disorder. Arch Gen Psychiatry 1995; 52:434.
Spencer T, Biederman J, Wilens , et al. Is attention deficit hyperactivity disorder in adults a valid diagnosis? Harvard Rev Psychiatry 1994; 1:326.
Wender PH, Reimherr FW, Wood DR. Attention deficit disorder (minimal brain dysfunction) in adults. Arch Gen Psychiatry 1981; 38:449.
Wender PH, Reimherr FW, Wood D, Ward M. A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry 1985; 142:547.
Wilens , Biederman J, Spencer TJ, et al. Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 1999; 19:257.
Wood DR, Reimherr FW, Wender PH, et al. Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report. Arch Gen Psychiatry 1976; 33:1453.
.
James I, Pearson R, Griffith D, et al. Effect of oxprenolol on stage fright in musicians. Lancet 1977; 2:952.
Kathol R, Noyes R Jr, Slymen DJ, et al. Propranolol in chronic anxiety disorders: a controlled study Arch Gen Psychiatry 1981; 37:1361.
Greendyke RM, Schuster DB, Wooton JA. Propranolol in the treatment of assaultive patients with organic brain disease. J Clin Psychopharmacol 1984; 4:282.
Mattes JA. Metoprolol for intermittent explosive disorder. Am J Psychiatry 1985; 142:1108.
Ratey JJ, Morrill R, Oxenkrug G. Use of propranolol for provoked and unprovoked episodes of rage. Am J Psychiatry 1983; 140:1356.
Ratey JJ, Sorgi P, O'Driscoll GA, et al. Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study. J Clin Psychiatry 1992; 53:41.
Lipinski JF, Zubenko GS, Cohen BM, et al. Propranolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 1984; 141:412.
Ratey JJ, Sorgi P, Polakoff S. Nadolol as a treatment for akathisia. Am J Psychiatry 1985; 142:640.
Kraus ML, Gottlieb LD, Horwitz RI, et al. Randomized clinical trial of atenolol in patients with alcohol withdrawal. N Engl J Med 1985; 313:905.
Dimsdale JE, Newton RP, Joist T. Neuropsychological side effects of beta-blockers. Arch Intern Med 1989; 149:514.
Griffin SJ, Friedman MJ. Depressive symptoms in propranolol users. J Clin Psychiatry 1986; 47:453.
Adier LA, Angrist B, Peselow E, et al. Clonidine in neuroleptic-induced akathisia. Am J Psychiatry 1987; 144:235.
Bond WS. Psychiatric indications for clonidine: the neuropharmacologic and clinical basis. J Clin Psychopharmacol 1986; 6:81.
Cohen DJ, Detlor J, Young JG, et al. Clonidine ameliorates Gilles de la Tourette syndrome. Arch Gen Psychiatry 1980; 37:1350.
Franks P, Harp J, Bell B. Randomized, controlled trial of clonidine for smoking cessation in a primary care setting. JAMA 1989; 262:3011.
|
|
Giannini AJ, Pascarzi GA, Loiselle RH, et al. Comparison of clonidine and lithium in the treatment of mania. Am J Psychiatry 1986; 113:1608.
Goodman WK, Charney DS, Price LH, et al. Ineffectiveness of clonidine in the treatment of the benzodiazepine withdrawal syndrome: report of three cases. Am J Psychiatry 1986; 143:900.
Hardy MC, Lecrubier Y, Widlocher D. Efficacy of clonidine in 24 patients with acute mania. Am J Psychiatry 1986; 143:1450.
Jouvent R, Lecrubier Y, Puech AJ, et al. Antimanic effect of clonidine. Am J Psychiatry 1980; 137:1275.
Leckman JF, Hardin MT, Riddle MA. Clonidine treatment of Gilles de la Tourette's Syndrome. Arch Gen Psychiatry 1991; 48:324.
San L, Cami J, Peir JM, et al. Efficacy of clonidine, guanfacine and methadone is the rapid detoxification of heroin addicts: a controlled clinical trial. Br J Addict 1990; 85:141.
Zubenko GS, Cohen BM, Lipinski JF, et al. Use of clonidine in treating neuroleptic-induced akathisia. Psychiatry Res 1984; 13:253.
Zubenko GS,Cohen BM, Lipinski JF, et al. Clonidine in the treatment of mania and mixed bipolar disorder. Am J Psychiatry 1984; 141:1617.
.
Barton BM, Gitlin MJ. Verapamil in treatment-resistant mania: an open trial. J Clin Psychopharmacol 1987; 7:101.
Dubovsky SL, Franks RD, Lifschitz M, et al. Effectiveness of verapamil in the treatment of a manic patient. Am J Psychiatry 1982; 139:502.
Dubovsky SL, Franks RD, Allen S, et al. Calcium antagonists in mania: a double-blind study of verapamil. Psychiatry Res 1986; 18:309.
Giannini AJ, Houser WL, Loiselle RH, et al. Antimanic effects of verapamil. Am J Psychiatry 1984; 141:1602.
Gitlin M, Weiss J. Verapamil as maintenance treatment in bipolar illness: a case report. J Clin Psychopharmacol 1984; 4:341.
.
Branchey L, Davis W, Lee KK, et al. Psychiatric complications of disulfiram treatment. Am J Psychiatry 1987; 14:1310.
Eneanya DL, Bianchine JR, Duran DO, et al. The actions and metabolic fate of disulfiram. Ann Rev Pharmacol Toxicol 1981; 21:575.
Fisher CM. Catatonia due to disulfiram toxicity. Arch Neurol 1989; 46:798.
Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism: a Veterans Administration cooperative study. JAMA 1986; 256:1449.
Fuller RK, Roth HP. Disulfiram for the treatment of alcoholism. Ann Intern Mod 1979; 90:901.
Kirubakaran V, Liskow B, Mayfield D, et al. Case report of acute disulfiram overdose. Am J Psychiatry 1983; 140:1513.
Sellers EM, Naranjo A, Peachey JE. Drugs to decrease alcohol consumption. N Engl J Med 1981;305:1255.
.
Roger SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: result of a multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 1996; 7:293.
.
Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271:985.
Watkins PB, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271:992.
.
Pelham WE, Aronoff HR, Midlam JK, et al. A comparison of ritalin and Adderall: efficacy and time course in children with attention-deficit/hyperactivity disorder. Pediatrics 1999; 103:43.
Pliszka SR. The use of psychostimulants in the pediatric patient. Pediatr Clin North Am 1998; 45:1085.
Swanson J, Wigal S, Greenhill L, et al. Objective and subjective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting. Psychopharmacol Bull 1998; 34:55.
|
|
.
AIMS ( )
β-
--
--
--
--
--
--
--
--
--
--
Bethanechol chloride
L- (3)
.
( )
. .
β-
. . (, )
( )
--
,
β-
()
β-
()
--
--
--
()
--
--
. . ()
,
--
-- -
--
--
--
--
--
. . ()
--
--
--
--
-- ,
--
--
--
--
--
-- -
--
--
--
--
--
--
--
--
-- ,
--
--
(AIMS)
|
|
()
-
--
--
--
--
--
--
--
--
--
--
--
-- -
--
-- ,
--
--
--
--
--
--
β-
/
--
--
-- ()
--
--
--
--
--
--
--
--
--
--
,
--
--
()
. . ()
--
--
. . ()
. (, )
.
. . ()
--
--
--
--
--
--
--
--
--
-- -
--
--
--
--
--
--
--
--
--
-- ,
()
--
--
-- ,
--
()
. .
,
ω-3
,
--
()
--
--
--
()
--
-- -
.
. . ()
--
--
--
(). .
,
. . ()
()
()
,
. . ()
,
. . ()
6
.
()
--
--
--
--
--
--
--
--
- ()
()
β-
3β-
.
. . (, )
. . ()
()
--
--
-- -
. . ()
()
--
--
--
--
,
,
( ). .
( ). .
,
,
()
--
--
--
--
--
--
--
--
--
--
(). .
,
()
--
--
-- -
--
(, )
-
. . ()
-
()
.
.
. . ()
--
--
( )
. . ()
()
.
. . ()
()
--
--
-- -
--
--
()
,
,
.
(, )
--
--
--
--
--
--
--
--
--
,
. . ()
,
()
()
--
--
-
()
--
--
--
()
-- -
()
--
--
--
--
--
-- -
--
--
--
--
()
--
--
--
--
--
--
. . ()
()
. . ()
,
( )
. . ()
.
. .
. . ()
(, , , , -S)
β-
3β-
-
--
--
--
--
--
--
--
--
--
--
--
--
--
(, )
()
--
--
--
--
--
--
--
--
--
. . ()
. . ()
.
. .
,
(),
()
β-
()
. . ()
,
()
--
--
,
()
--
--
--
()
(),
()
--
--
--
--
--
-- -
--
--
--
--
--
.
()
--
--
. . ()
,
,
,
,
(). .
()
--
--
--
--
--
β-
. . (, , , , -S)
. . ()
()
.
- ()
()
--
()
--
--
--
-3- (ω-3-)
,
. . ()
. .
(-)
.
. . ()
β-
,
. . ()
(, )
--
--
--
--
()
--
--
. . (, )
()
()
--
--
,
()
()
()
/
. . ()
. . (, )
--
--
--
--
--
--
--
()
()
β-
--
--
--
--
--
--